Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

CryoLife CryoPatch SG: Cardiac patch gains 510(k) clearance for repair or reconstruction of the right ventricular outflow tract, announced Aug. 12. Processed with CryoLife's proprietary SynerGraft technology, the human collagen matrix device addresses a niche U.S. market worth about $15 million, according to the company. Right ventricular outflow tract repair or reconstruction is commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus and Pulmonary Atresia. The device is available in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch. Shipments will start by the end of September, CryoLife says
Advertisement

Related Content

Kinetic Concepts' Five-Year Plan Centers On New Products, Market Expansion
Kinetic Concepts' Five-Year Plan Centers On New Products, Market Expansion

Topics

Advertisement
UsernamePublicRestriction

Register

MT027795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel